DLL3 is an emerging therapeutic target in small cell lung cancer and other neuroendocrine carcinomas, with 1 FDA-approved therapy and several others under investigation.
Catherine B. Meador, MD, PhD
Advertisement
Articles by Catherine B. Meador, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
2
FDA Approves Lumateperone With Antidepressant Use for Major Depressive Disorder
3
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
4
Gedatolisib Triplet Shows Significant PFS Benefit in HR+/HER2– Breast Cancer
5
